(Q32019381)

5 July 2017

title

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler (English)

1 reference

5 July 2017

0 references

G Bensch

1

1 reference

5 July 2017

R J Lapidus

2

1 reference

5 July 2017

B E Levine

3

1 reference

5 July 2017

W Lumry

4

1 reference

5 July 2017

U Yegen

5

1 reference

5 July 2017

P Kiselev

6

1 reference

5 July 2017

G Della Cioppa

7

1 reference

5 July 2017

publication date

1 January 2001

1 reference

Annals of Allergy, Asthma & Immunology

5 July 2017

published in

1 reference

5 July 2017

volume

86

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

19-27

1 reference

Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Beta-adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting beta 2-adrenoceptor agonist formoterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Rapid onset of action of inhaled formoterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Long-Acting Inhaled Beta Agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Dose-response of inhaled drugs in asthma. An update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Long- versus short-acting beta 2-agonists. Implications for drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Assessing the use of metered dose inhalers by adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

Current therapies for asthma. Promise and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962351-4

7 January 2021

10.1016/S1081-1206(10)62351-4

Identifiers

DOI

1 reference

5 July 2017

1 reference